22 May 2013
Keywords: promising, results, alnylam, amd, rnai, treatment, usa-based
Article | 07 March 2005
USA-based RNAi therapeutics company Alnylam Pharmaceuticals has posted encouraging in vivo efficacy data on the use of its RNA interference
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 March 2005
© 2013 thepharmaletter.com